Asthma Forecast and Market Analysis to 2024

Asthma Forecast and Market Analysis to 2024

  • February 2018 •
  • 680 pages •
  • Report ID: 5367945 •
  • Format: PDF
Disease Overview
Asthma is a chronic respiratory disease characterized by recurrent breathlessness and wheezing, which occur in acute events known as attacks. These attacks can vary significantly in frequency and severity, and consist of swelling of the lining of the bronchial tubes, which narrows airways and results in a reduction of airflow into and out of the lungs. Collaborators of the Global Initiative for Asthma believe that as many as 300 million people worldwide are greatly impacted by asthma in their daily lives, whether through asthma symptoms not allowing them to undertake simple day-to-day activities or through being unable to complete assigned tasks at work.

Recent events and opinion
Biologic therapies will drive growth in the asthma market despite generic erosion of key ICS/LABA combinations.
Datamonitor Healthcare’s survey of 221 physicians sheds light on treatment patterns and prescribing influences.
There were an estimated 51.3 million diagnosed prevalent cases in 2016; this is predicted to rise due to population growth.
Competition for eosinophilic asthma is intensifying with the recent approval of Fasenra, the third-to-market IL-5 inhibitor.
Bolstered by strong clinical data, Dupixent is poised to have a large impact on the biologic therapies market.
Payers’ fear of the budget impact of newly approved IL-5 inhibitors will prompt tighter access control.